small molecule

TORISEL

TEMSIROLIMUS

Loss of exclusivityNovember 2032latest FDA-listed patent expiry
CompanyPF PRISM CV

Drug detail

Brand nameTORISEL
Active ingredientTEMSIROLIMUS
Strength25MG/ML (25MG/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalMay 2007
Marketing statusRX

Listed patents

PatentExpiresType
8791097*PEDNovember 2032
8791097May 2032use U-1550
8026276*PEDJuly 2026
8026276January 2026product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

TORISEL patent cliff — loss of exclusivity November 2032 | CliffBio